Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 25,000 shares at $44.90 ($1.1M) on 2025-03-05, disclosed to the SEC on 2025-03-07.
Scheduled sale ($1.1M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.40 | 9,338 | $415K | 37.2% |
| 2 | $44.40 | 9,338 | $415K | 37.2% |
| 3 | $44.90 | 3,162 | $142K | 12.8% |
| 4 | $44.90 | 3,162 | $142K | 12.8% |
| Total | $44.53 avg | 25,000 | $1.1M | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |